Skip to Main Content

Paper Details

A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.
Cell Rep Med
12
2021
ADC, D3, DNA, Fab, GPC2, Glypican 2, MYCN, MYCN-driven oncoprotein, PBD, SCLC, SCLC tumor, SCLCs, core, core GPC2 extracellular domain, human, human GPC2 antibody, neuroblastoma, neuroblastoma and, neuroblastoma stem, neuroblastoma stem cell compartment, pyrrolobenzodiazepine, small-cell lung cancer, small-cell lung cancers, tumor
Author NameAffiliation
Maria V LaneDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Daniel MartinezChildren's Hospital of Philadelphia
Daniel MartinezChildren's Hospital of Philadelphia
Khushbu PatelDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Komal S RathiDepartment of Biomedical and Health Informatics and Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Komal S RathiDepartment of Biomedical and Health Informatics and Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Yimei LiPerelman School of Medicine, University of Pennsylvania
Dimiter S DimitrovUniversity of Pittsburgh School of Medicine
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
John M MarisPerelman School of Medicine at the University of Pennsylvania
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
John M MarisPerelman School of Medicine at the University of Pennsylvania
Kristopher R BosseDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Kristopher R BossePerelman School of Medicine at the University of Pennsylvania
  • 1 - 14

Datasets

Release 1.2